Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparing Video and Direct Laryngoscopy in Critically Ill Patients: Rational Study Design Is Important.

Critical care medicine·2017

Same author

Genome-wide characterization and expression profiling of the NAC genes under abiotic stresses in Cucumis sativus.

Plant physiology and biochemistry : PPB·2017

Same author

Comparing performance of Bonfils fiberscope and GlideScope videolaryngoscope for awake intubation.

Journal of clinical anesthesia·2017

Same author

Use of dual priming oligonucleotide system-based multiplex RT-PCR combined with high performance liquid chromatography assay for simultaneous detection of five enteric viruses associated with acute enteritis.

Journal of virological methods·2017

Same author

Multichannel and Wide-Angle SAR Imaging Based on Compressed Sensing.

Sensors (Basel, Switzerland)·2017

Same author

Actein inhibits glioma growth via a mitochondria-mediated pathway.

Cancer biomarkers : section A of Disease markers·2017

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

[Low-dose tadalafil improves arterial erectile dysfunction].

Zhi-Peng Xu¹, Yun Chen, Chao Sun

¹Department of Andrology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China. xuzhipengyi@163.com

Zhonghua Nan Ke Xue = National Journal of Andrology

|March 12, 2010

Summary

This summary is machine-generated.

Low-dose tadalafil significantly improved erectile function in men with arterial erectile dysfunction. Treatment increased peak systolic velocity (PSV) in the cavernosal artery, enhancing blood flow and sexual health.

Related Experiment Videos

Last Updated: Jun 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Urology
Cardiovascular Medicine
Pharmacology

Background:

Arterial erectile dysfunction (ED) is a common condition affecting penile blood flow.
Phosphodiesterase type 5 (PDE5) inhibitors are a standard treatment for ED.
Low-dose tadalafil's efficacy in arterial ED requires further evaluation.

Purpose of the Study:

To assess the impact of low-dose tadalafil on arterial erectile dysfunction.
To evaluate changes in penile hemodynamics and erectile function.

Main Methods:

A study involving 43 patients diagnosed with arterial ED.
Participants received 5 mg tadalafil on alternate days for 4 weeks.
Evaluations included the International Index of Erectile Function (IIEF-5) and cavernosal artery peak systolic velocity (PSV) via Doppler ultrasonography after prostaglandin E1 injection.

Main Results:

Significant improvements were observed in IIEF-5 scores post-treatment (P < 0.01).
A statistically significant increase in cavernosal artery PSV was recorded (P < 0.01).
These findings indicate enhanced penile arterial blood flow.

Conclusions:

Low-dose tadalafil demonstrates a significant positive effect on arterial erectile dysfunction.
The treatment improves cavernosal artery hemodynamics, specifically PSV.
Tadalafil offers a viable therapeutic option for improving erectile function in patients with arterial ED.